| Literature DB >> 28821425 |
Kalani Karunaratne1, Nicholas Luedtke1, Daniel M Quinn2, Amnon Kohen1.
Abstract
Thymidylate is synthesized de novo in all living organisms for replication of genomes. The chemical transformation is reductive methylation of deoxyuridylate at C5 to form deoxythymidylate. All eukaryotes including humans complete this well-understood transformation with thymidylate synthase utilizing 6R-N5-N10-methylene-5,6,7,8-tetrahydrofolate as both a source of methylene and a reducing hydride. In 2002, flavin-dependent thymidylate synthase was discovered as a new pathway for de novo thymidylate synthesis. The flavin-dependent catalytic mechanism is different than thymidylate synthase because it requires flavin as a reducing agent and methylene transporter. This catalytic mechanism is not well-understood, but since it is known to be very different from thymidylate synthase, there is potential for mechanism-based inhibitors that can selectively inhibit the flavin-dependent enzyme to target many human pathogens with low host toxicity.Entities:
Keywords: Enzyme; Flavin; Mechanisms; N5-flavin adduct; Thymidylate; Thymidylate synthase
Mesh:
Substances:
Year: 2017 PMID: 28821425 PMCID: PMC5728703 DOI: 10.1016/j.abb.2017.08.011
Source DB: PubMed Journal: Arch Biochem Biophys ISSN: 0003-9861 Impact factor: 4.013